• Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
  
• Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
  

PubMed=10496349; DOI=10.1038/sj.bjc.6690684; PMCID=PMC2362859
Culig Z., Hoffmann J., Erdel M., Eder I.E., Hobisch A., Hittmair A., Bartsch G., Utermann G., Schneider M.R., Parczyk K., Klocker H.
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Br. J. Cancer 81:242-251(1999)

PubMed=34402095; DOI=10.1002/pros.24210; PMCID=PMC8460612
Haffner M.C., Bhamidipati A., Tsai H.K., Esopi D.M., Vaghasia A.M., Low J.-Y., Patel R.A., Guner G., Pham M.-T., Castagna N., Hicks J.L., Wyhs N., Aebersold R., De Marzo A.M., Nelson W.G., Guo T.-N., Yegnasubramanian S.
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
Prostate 81:1159-1171(2021)

PubMed=38892296; DOI=10.3390/ijms25116111; PMCID=PMC11172770
Beatson E.L., Risdon E.N., Napoli G.C., Price D.K., Chau C.H., Figg W.D. Sr.
Genomic characterization of preclinical prostate cancer cell line models.
Int. J. Mol. Sci. 25:6111.1-6111.19(2024)